COVID-19: Information on ASPIRA LABS Operations

Click to Learn More
  • Home
  • Recent News and Upcoming Events

Recent News and Upcoming Events

Recent News


  • ASPiRA Labs Announces OVA1 Contract with Louisiana Blue Cross Blue Shield

    AUSTIN, Texas, October 31, 2017 – ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and exclusive distributor of OVA1 (Multivariate Index Assay, or MIA), an ovarian cancer risk assessment test, today announced it has entered into an agreement with Blue Cross Blue Shield of Louisiana. “ASPiRA Labs has increased in-network coverage for OVA1 with BCBS of…

  • ASPiRA Labs Lands Strategic Managed Care Coverage and Medicaid Licensure for OVA1®

    AUSTIN, Texas, Oct. 27, 2017 /PRNewswire/ — ASPiRA Labs, a Vermillion company (VRML), today announced it has entered into agreements with Joint Venture Hospital Laboratories, LLC (“JVHL”), QCA Health Plan of Arkansas, Inc. (d/b/a Qualchoice), Louisiana State Medicaid program, and Arizona State Medicaid Program to provide coverage for its in vitro diagnostic test, OVA1®. “We…

  • Vermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8th

    Vermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8th  AUSTIN, Texas, October 25, 2017 — Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its third quarter 2017 financial results on Wednesday, November 8, 2017, followed by an investor…

  • Vermillion Reports Second Quarter 2017 Results

    Link to PDF with Financials – VRML_08 09 2017 Earnings Release Conference Call at 4:30 p.m. ET Today AUSTIN, Texas — August 9, 2017 — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the second quarter ended June 30, 2017.   Valerie Palmieri, President and…

  • Vermillion Reports First Quarter 2017 Results

    Vermillion Reports First Quarter 2017 Results Conference Call at 8:30 a.m. ET Today AUSTIN, Texas — May 11, 2017 — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the first quarter ended March 31, 2017. Valerie Palmieri, President and CEO of Vermillion, Inc., stated, “The…

Investor Relations